Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

KIO 101

Next Previous
Search
Drug Profile

KIO 101

Alternative Names: KIO 101; PaniDrop; PaniJect; PP-001 - Panoptes Pharma

Latest Information Update: 28 Jan 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 4SC Discovery
  • Developer Kiora Pharmaceuticals; Panoptes Pharma
  • Class Anti-inflammatories; Eye disorder therapies; Small molecules
  • Mechanism of Action Dihydroorotate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Dry eyes
  • Phase I/II Uveitis
  • Preclinical Unspecified
  • No development reported Conjunctivitis; Infectious conjunctivitis; Keratoconjunctivitis

Most Recent Events

  • 28 Jan 2024 No recent reports of development identified for phase-I development in Conjunctivitis in Unknown (Ophthalmic, Drops)
  • 28 Jan 2024 No recent reports of development identified for phase-I development in Dry-eyes in Unknown (Ophthalmic, Drops)
  • 21 Sep 2023 Kiora Pharmaceuticals suspends a phase II trial for Dry eyes (In adults, In elderly) in Australia (Ophthalmic) (Drops) (NCT05629364)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top